A profound elevation of blood pressure on exercises or after withdrawal of antihypertensive drugs has been reported in patients with a history of acceleratedmalignant hypertension. We tested the hypothesis that severe endothelial dysfunction is responsible for the profound hypertensive response in these patients. Responses of blood pressure, heart rate and plasma cyclic guanosine monophosphate to intravenously infused L-arginine, a precursor of nitric oxide, was investigated in hypertensive patients with (group A) or without any history of accelerated-malignant hypertension (group B) in order to evaluate endothelial function. Casual blood pressure or severity of hypertension was not different between group A and B. Infusion of L-arginine decreased mean blood pressure in group B (97.4 ؎ 8.7 to 81.7 ؎ 6.9 mm Hg), but not in group A (99.0 ؎ 10.2 to 101.5 ؎ 8.7 mm Hg). Plasma levels of cyclic
Introduction
Development of antihypertensive drugs in the last two decades has markedly improved the prognosis of accelerated-malignant hypertension (A-MHT). 1, 2 Blood pressure (BP) can be controlled adequately in most cases with A-MHT and, in the chronic phase, casual BP and severity of hypertension are not different from those in hypertensive patients without any history of A-MHT. Although severe elevation in diastolic BP and severe retinopathy (Keith-Wagener (KW) III or IV), features of A-MHT in the acute phase, 3 might disappear after long-term antihypertensive treatment, 4 a profound pressor response induced by static or dynamic exercises or after withdrawal of antihypertensive drugs has been reported. 4 Since A-MHT is characterised by severe endothelial damage and the endothelial dysfunction is one of the most important factors for initiation and progression of A-MHT, 5 responses in patients with a history of A-MHT may be attributed by the endothelial dysfunction which could persist even in the chronic phase. The endothelium plays an important role in regulation of BP by releasing potent vasoactive factors including nitric oxide. 7 Since the molecule is produced from L-arginine by constitutive nitric oxide synthase, intravenous administration of L-arginine has been considered as one of the methods to evaluate endothelial function. 8 Indeed, infusion of L-arginine induces hypotension via a release of nitric oxide. 8 L-arginine infusion test has long been established as a means of assessing release of growth hormone and insulin. Although growth hormone, insulin, glucagon, and prolactin are released by Larginine, 9 none of these hormones can explain the hypotensive effect induced by L-arginine. Thus, Larginine infusion is one of the noninvasive methods for evaluation of endothelium to release nitric oxide. 10 The present study was designed to investigate the endothelial function in hypertensive patients with a history of A-MHT. We evaluated endothelial function by L-arginine infusion and compared the response in patients with and without a history of A-MHT.
Journal of Human Hypertension

Materials and methods
Subjects
Twenty essential hypertensive patients with (group A, n ϭ 10) or without a past history of A-MHT (group B, n ϭ 10) were recruited to this study (Table  1) (Table 1) . There was no difference in characteristics of the subjects listed in the table between group A and B. They were treated under the diagnosis of hypertension for 10.8 Ϯ 2.2 years (4.8 to 15.6). Calcium channel blockers (manidipine hydrochloride, amlodipine besilate, or benidipine hydrochloride) and ␤-blockers (bisoprolol fumarate, or metoprolol tartrate) were included in the current treatment in the both groups. Combination of antihypertensive agents was not different in group A and B. Carefully taken history, physical examination, laboratory and radiological investigations confirmed the diagnosis of essential hypertension. All patients were without history of diabetes mellitus or hyperlipidaemia. All patients gave written, informed consent on forms approved by the Human Studies Committee at the Nagoya City University Hospital before the study.
Protocol
The subjects fasted overnight, but took antihypertensive agents as usual, and were allowed to rest in a supine position in a quiet, comfortable room (22°C to 25°C) in the morning. A polyethylene catheter was inserted into the right antecubital vein for the infusion of L-arginine (L-arginine hydrochloride, 100 mg/ml, Morishita Co, Osaka, Japan) and another catheter was inserted into left radial vein to obtain blood samples for a measurement of cyclic guanosine monophosphate (cGMP) as an indicator of nitric oxide production before and after L-arginine infusion. After a 30-min supine rest, L-arginine (500 mg/kg) was infused intravenously for 30 min using an infusion pump (STC-508, Termo Co, Tokyo, Japan). BP and heart rate (HR) were measured every 2 min throughout the study using an automatic device (Nippon Colin Inc, Tokyo, Japan) on the upper left arm.
Calculations and statistical analysis
Data were expressed as mean Ϯ s.d. Mean BP (MBP) was calculated from the following formula: MBP ϭ diastolic BP +1/3 pulse pressure. Differences between group A and B were evaluated using Student's unpaired t-test (MAP, HR and cGMP). Changes of MAP and HR were analysed using ANOVA for repeated measurements followed by Scheffe's F-test. Relations between variables were analysed by calculating correlation coefficients. Statistical significance was assumed when P Ͻ 0.05.
Results
Effects of L-arginine
Hemodynamics (Figure 1 the depressor effect disappeared within 10 min after the cessation of the infusion. Maximum reduction of MBP was achieved at the end of the infusion (97.4 Ϯ 8.7 to 81.7 Ϯ 6.9 mm Hg, P Ͻ 0.01). Both systolic and diastolic BP was reduced by L-arginine (data not shown). In contrast, L-arginine did not affect BP in group A (99.0 Ϯ 10.2 to 101.5 Ϯ 8.6 mm Hg, NS). Baseline HR was not different between group A and B before the infusion, and was not altered during the infusion in either group.
cGMP: No significant difference was observed in plasma concentrations of cGMP between group A (5.4 Ϯ 1.9 pmol/ml) and B (5.4 Ϯ 2.0 pmol/ml) before the infusion of L-arginine. L-arginine infusion increased cGMP in group B (7.7 Ϯ 1.7 pmol/ml, P Ͻ 0.01), but not in group A (5.9 Ϯ 2.1 pmol/ml) ( Figure  2) . A significant correlation was observed between decrease in MBP and increase in plasma levels of cGMP (r ϭ 0.85, P Ͻ 0.001) (Figure 3 ).
Discussion
Our study demonstrated that L-arginine induced hypotension in patients without any history of A-MHT. Since L-arginine is a precursor of nitric oxide,
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the infusion of the amino acid may stimulate endothelial nitric oxide production, which leads to vasodilatation through activation of guanylate cyclase in the vascular smooth muscle. 11 Indeed, plasma levels of cGMP were increased after the infusion of L-arginine in patients without any history of A-MHT and a significant correlation between decrease in MBP and increase in plasma levels of cGMP. The depressor effect obtained in the present study was much more pronounced as compared to that reported in healthy volunteers 8 using the same protocol as in our study, implying that chronic antihypertensive treatment might have improved, at least in part, the impaired endothelial function in the patients without any history of A-MHT. This finding confirms previous reports obtained in animals 12, 13 and humans, 14, 15 though effects of calcium channel blockers on endothelial function are still unclear and under controversy. 14, 15 In contrast to the patients without any history of A-MHT, the depressor effect of L-arginine was blunted in patients with a history of A-MHT, indicating that the endothelial function, in terms of relaxation, is damaged in the patients. There is no report investigating endothelial function of A-MHT in chronic phase. However, the present results suggest that endothelial dysfunction of A-MHT must persist in the chronic phase even though other characteristics of A-MHT observed in acute phase seem to have disappeared. Chronic administration of antihypertensive drugs, at least those used in the present study, may not have favourable effects on the endothelial function. We used calcium channel blockers as main antihypertensive agents for the treatment of A-MHT. 1, 4 It is possible that angiotensin-converting enzyme inhibitors might improve the endothelial function as reported in hypertensive patients without any history of A-MHT. 14, 16 Alternatively, endothelial dysfunction in A-MHT may be irreversible. Indeed, widespread endothelial damage is one of the most important features in A-MHT. 17 The endothelial dysfunction which persists in the chronic phase of A-MHT may explain the profound pressor responses induced by static or dynamic exercises and after withdrawal of antihypertensive drugs in patients with a history of A-MHT, whose casual BP, antihypertensive drugs used, or severity of hypertension are not apparently different from hypertensive patients without any history of A-MHT. However, we cannot completely deny the possibility that reduced sensitivity of vascular smooth muscle to nitric oxide may contribute to the impaired response to L-arginine in patients with a history of A-MHT.
In the previous studies, L-arginine infusion increased HR. 8, 18 However, HR was not altered during L-arginine infusion in our study. The present study was performed under medical treatment with antihypertensive drugs including ␤-blockers. This may be the reason why an increase in HR was not observed during the infusion of L-arginine.
Intravenous infusion of L-arginine is a non-invasive test for evaluation of endothelial function, but the infusion has other nonspecific effects than release of nitric oxide; changes in plasma electro-lytes, osmolality and increase in plasma levels of atrial natriuretic peptide (ANP). 18 However, Llysine, that also has similar effects on electrolytes, osmolality, and ANP, does not produce hypotension. 18 Therefore, L-arginine-induced vasodilatation is mediated by an increase of nitric oxide production.
In conclusion, severe endothelial dysfunction persists in hypertensive patients with a history of A-MHT even though the BP is adequately controlled. This may be responsible for profound pressor responses observed after exercises or withdrawal of antihypertensive agents in hypertensive patients with a history of A-MHT.
